Friday, September 12, 2014 1:49:11 AM
Mendelspod host Theral Timpson kicked off a new podcast series this week on long-read sequencing that will include interviews with luminaries in the genomics field. Check out this introductory article from Timpson for an explanation of why scientists are demanding longer reads to meet their research goals.
The first interview is with Mike Snyder at Stanford, who has published recent papers in Nature Biotechnology and PNAS using Single Molecule, Real-Time (SMRT®) Sequencing for transcriptome analysis and demonstrated that long reads enable full coverage of RNA molecules. He discusses that work and his views on long-read sequencing and transcriptomics on the show. Here are some highlights:
On the state of transcriptomics
Without using long-read sequencing, the way transcriptomes are figured out is “crazy,” Snyder explains. “We take RNA, we blow it up into little fragments, and then we try and assemble them back together to see what the transcriptome looked like in the first place. And that’s a horrible way to do this because what we’re really trying to do is understand all of the different isoforms of a transcript….So when you blow them up and try to reassemble them back together you can’t always figure out which parts of the puzzle belong together.” (This reminds us of a clever cartoon in Nature Methods last year, subscription required.)
The power of long-read sequencing
By nature, long-read sequencing can avoid ‘blowing up’ the transcripts, because as Snyder has demonstrated in his studies, it is possible to generate full-length transcripts using SMRT Sequencing.
“The power of long-read sequencing is really to be able to capture all of the information in its intact form without trying to solve a jigsaw puzzle that you may have put together wrong.” Snyder explains that misassembling transcripts can make it impossible to understand what is going on. For example, different isoforms of the same tumor gene have very different functions and may be either healthy or oncogenic.
On the $1000 genome
“Has the race to the $1000 genome been at the expense of quality?” Timpson asked Snyder. “Yes,” he replied. “I think people’s eyes are opening to that.” Based on what is currently considered the “$1,000 Genome” (which Snyder points out cannot actually be commercially purchased today for $1,000), he says, “the quality is still not there, there’s still significant gaps.”
“People don’t realize this but there are still several hundred gaps in the human genome that have never been closed,” Snyder explains. And, ironically, in the process of attempting to fix these gaps in the reference genome, researchers end up uncovering more errors, “so the number of gaps in the human genome has stayed fairly constant over the last 10 years or so,” he adds.
Snyder believes that PacBio’s SMRT Sequencing provides one solution to this problem, by spanning gaps, resolving structural variation and providing the ‘gold standard’ in quality in sequencing today.
Stay tuned
This series will also include interview with Eric Schadt, Gene Myers, and Dan Geraghty. We’ll be tuning in to hear what these great scientists have to say, and we hope you do, as well.
http://blog.pacificbiosciences.com/2014/09/the-rise-of-long-reads-mendelspod.html?utm_content=buffer1bda3&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM